Garvan Institute of Medical Research

91 items matching your search terms.

Timing and context: important considerations in the return of genetic results to research participants: McBride, K. A.; Hallowell, N.; Tattersall, M. H.; Kirk, J.; Ballinger, M. L.; Thomas, D. M.; Mitchell, G.; Young, M. A.;; Journal of Community Genetics 7 (1) :11-20, 2016

Mouse Models of Tumor Immunotherapy: Ngiow, S. F.; Loi, S.; Thomas, D.; Smyth, M. J.;; Advances in Immunology 130 :1-24, 2016

Diagnosis and Management of Hereditary Sarcoma: Thomas, D. M.; Ballinger, M. L.;; Recent Results Cancer Res 205 :169-89, 2016

Clinical Overview of MDM2/X-Targeted Therapies: Burgess, A.; Chia, K. M.; Haupt, S.; Thomas, D.; Haupt, Y.; Lim, E.;; Frontiers in Oncology 6 :7, 2016

Cancer 2015: a longitudinal, whole of system study of genomic cancer medicine: Thomas, D.M.; Fox, S.; Lorgelly, P.K.; Ashley, D.; Richardson, G.; Lipton, L.; Parisot, J. P.; Lucas, M.; McNeil, J.; Wright M for the Cancer 2015 Investigators, .;; DRUG DISCOVERY TODAY 20 (12) :1429-32, 2015 10.1016/j.drudis.2015.10.009.

Etiologic, environmental and inherited risk factors in sarcomas: Thomas, D. M. ; Ballinger, M. L.;; JOURNAL OF SURGICAL ONCOLOGY 111 (5) :490-495, 2015

Accepting risk in the acceleration of drug development for rare cancers: Ashley, D. ; Thomas, D.M. ; Gore, L. ; Carter, R. ; Zalcberg, J. R. ; Otmar, R. ; Savulescu, J.;; LANCET ONCOLOGY 16 (4) :e190-194, 2015

Clinical implications of genomics for cancer risk genetics.: Thomas, D. M.; James, P.A.; Ballinger, M. L.;; LANCET ONCOLOGY 16 :e303-308, 2015

Precision medicine for advanced pancreas cancer: the individualized molecular pancreatic cancer therapy (IMPaCT) trial: Chantrill, L. A. ; Nagrial, A. M. ; Watson, C. ; Johns, A. L. ; Martyn-Smith, M. ; Simpson, S. ; Mead, S. ; Jones, M. D. ; Samra, J. S. ; Gill, A. J. ; Watson, N. ; Chin, V. T. ; Humphris, J. L. ; Chou, A. ; Brown, B. ; Morey, A. ; Pajic, M. ; Grimmond, S. M. ; Chang, D. K. ; Thomas, D. ; Sebastian, L. ; Sjoquist, K. ; Yip, S. ; Pavlakis, N. ; Asghari, R. ; Harvey, S.; CLINICAL CANCER RESEARCH 21 (9) :2029-2037, 2015

Distinguishing activity from progress: Tattersall, M. H. ; Thomas, D. M.;; LANCET ONCOLOGY 16 (16) :1586-8, 2015

A genome-wide scan identifies variants in NFIB associated with metastasis in patients with osteosarcoma: Mirabello, L.; Koster, R.; Moriarity, B. S.; Spector, L. G.; Meltzer, P. S.; Gary, J.; Machiela, M. J.; Pankratz, N.; Panagiotou, O. A.; Largaespada, D.; Wang, Z.; Gastier-Foster, J. M.; Gorlick, R.; Khanna, C.; Caminada de Toledo, S. R.; Petrilli, A. S.; Patino-Garcia, A.; Sierrasesumaga, L.; Lecanda, F.; Andrulis, I. L.; Wunder, J. S.; Gokgoz, N.; Serra, M.; Hattinger, C.; Picci, P.; Scotlandi, K.; Flanagan, A. M.; Tirabosco, R.; Fernanda Amary, M.; Halai, D.; Ballinger, M. L.; Thomas, D. M.;; Cancer Discovery 5 (9) :920-931, 2015

""Cancer 2015"": A Prospective, Population-Based Cancer Cohort-Phase 1: Feasibility of Genomics-Guided Precision Medicine in the Clinic: Parisot, J. P.; Thorne, H.; Fellowes, A.; Doig, K.; Lucas, M.; McNeil, J. J.; Doble, B.; Dobrovic, A.; John, T.; James, P. A.; Lipton, L.; Ashley, D.; Hayes, T.; McMurrick, P.; Richardson, G.; Lorgelly, P.; Fox, S. B.; Thomas, D. M.;; Journal of Personalized Medicine 5 (4) :354-369, 2015

The growing problem of benign connective tissue tumours: Thomas, D. M.;; LANCET ONCOLOGY 16 (8) :879-880, 2015

The psychosocial effects of a whole body MRI screening trial in sarcoma patients with a germline Tp53 mutation: McBride, K. A. ; Young, M. A. ; Schlub, T. E. ; Kirk, J. ; Tattersall, M. H. N. ; Ballinger, M. ; Thomas, D. ; Mitchell, G.;; Asia-Pacific Journal of Clinical Oncology 11 :178-178, 2015